This comparison examines the effectiveness of povidone-iodine and chlorhexidine in managing iatrogenic wounds in surgical patients. Both antiseptics are commonly used to prevent postoperative infections, but they differ in mechanism, efficacy, and safety profiles. Povidone-iodine releases iodine, which acts broadly against bacteria, viruses, and fungi, while chlorhexidine disrupts cell membranes, providing rapid bactericidal action. Studies suggest that chlorhexidine may offer longer-lasting antibacterial effects, but povidone-iodine has a wider antimicrobial range. Optimal choice depends on patient needs, wound type, and potential for adverse reactions, emphasizing the need for tailored antiseptic strategies in wound care.

Start Date07 Jan 2025

Sponsor / Collaborator-

NCT06627270 / Not yet recruitingPhase 2IIT

A Phase II Single-arm Cohort Study Establishing the Effect of Antibiotic Treatment on Intratumoral Bacteria in Surgical Patients With Oral Cancer

The goal of this phase II single arm clinical study is to evaluate the effect of antibiotics (metronidazole) and oral chlorhexidine (CHX) in reducing the bacteria load within tumors of patients undergoing surgery for oral cancer.

Start Date01 Dec 2024

Sponsor / Collaborator

The Case Comprehensive Cancer Center

CTRI/2024/09/074027 / Not yet recruitingPhase 2/3IIT

Comparative Evaluation of Efficacy of Herbal Mouthwash (Oralife) with Chlorhexidine Mouthwash (Rexidine SRS) in Generalized Chronic Periodontitis Patients- A Randomized Clinical Trial - NIL

Start Date10 Nov 2024

Sponsor / Collaborator-

100 Clinical Results associated with Chlorhexidine Acetate

100 Translational Medicine associated with Chlorhexidine Acetate

100 Patents (Medical) associated with Chlorhexidine Acetate

731

Literatures (Medical) associated with Chlorhexidine Acetate

01 Jan 2025·JOURNAL OF ETHNOPHARMACOLOGY

Dental applications of Punica granatum L. in the treatment of gingivitis: A review of ethnomedicinal uses, randomized clinical trials, and antibacterial potential against Porphyromonas gingivalis

Review

Author: Domingos da Silva, Jadson Mathyas ; Lima Bezerra, José Jailson

ETHNOPHARMACOLOGICAL RELEVANCE:

Mouthwashes based on medicinal plants have demonstrated benefits in controlling plaque and inflammation, acting positively on the oral hygiene of patients with gingivitis. In traditional medicine, Punica granatum L. has been used to treat oral diseases in countries in Europe, Asia, North America, and Africa.

AIM OF THE STUDY:

The present study aimed to conduct a comprehensive review on the dental applications of Punica granatum L. for the treatment of gingivitis, including ethnomedicinal uses, analysis of randomized clinical trials, antibacterial activity against Porphyromonas gingivalis, mechanisms of action of phytochemicals isolated from this plant, and preclinical toxicity.

MATERIALS AND METHODS:

The literature was retrieved from Google Scholar, PubMed®, SciELO, and ScienceDirect®, since the first report published on the topic in 2001 until March 2024.

RESULTS:

Several clinical trials have demonstrated that mouthwashes containing P. granatum have equal or better efficacy than chlorhexidine in treating patients with gingivitis, confirming the indications for use of this plant by traditional communities. However, reports on the in vitro antibacterial activity of extracts from the fruits of this plant have not shown clinical relevance against the pathogen P. gingivalis. The ellagitannin punicalagin isolated from P. granatum has shown potential against several strains of Gram-positive and Gram-negative bacteria, but, to date, this compound has not yet been tested against P. gingivalis. It is likely that the mechanisms of action of flavonoids, such as quercetin, are involved in the inhibition of the activities of the RgpA, RgpB, and Kgp proteases of P. gingivalis.

CONCLUSIONS:

In summary, natural products obtained from P. granatum do not present toxic side effects and can be considered as possible substitutes of commercial products recommended for the treatment of gingivitis and other oral diseases.

31 Dec 2024·Journal of Oral Microbiology

Inhibitory effect of helium cold atmospheric plasma on cariogenic biofilms

Article

Author: Doria, Anelise Cristina Osorio Cesar ; Figueira, Leandro Wagner ; Koga-Ito, Cristiane Y. ; Kostov, Konstantin Georgiev ; Bessa Muniz, Ana ; Castaldelli Nishime, Thalita Mayumi

This study aimed to determine the effects of low-temperature plasma jet produced in gas helium (LTP-helium) on cariogenic biofilms composedby Streptococcusmutans, Streptococcus sanguinis and Streptococcus gordonii, and also by the combination of Candida albicans, Lactobacillus acidophilus and S. mutans. Biofilms were treated for 1, 3, 5, and 7 minutes. A 0.12% chlorhexidine solution was used as the positive control and sterile physiologic solution was the negative control. Biofilm viability was analyzed by viable cell recovery, scanning electron microscopy, and confocal laser scanning microscopy. All assays were performed intriplicate in three independent experiments. Multispecies biofilms exposed to LTP-helium had a significant reduction in viability when compared to the negative control (p < 0.0001). For biofilm formedby S. mutans, S. sanguinis, and S. gordonii, LTP treatments for 5 and 7 minutes caused similar reduction of morethan 2 log₁₀. Also, a significant reduction in the viability of biofilms formedby C. albicans, L. acidophilus, and S. mutans was detected (p < 0.0001). In conclusion, LTP-helium reduced theviability of cariogenic biofilms with different microbial compositions, which indicates that LTP-helium is a potential tool for developing new protocols for dental caries prevention and treatment.

31 Dec 2024·Journal of Oral Microbiology

Silica nanoparticles containing nano-silver and chlorhexidine to suppress Porphyromonas gingivalis biofilm and modulate multispecies biofilms toward healthy tendency

Article

Author: Liu, Fei ; Wang, Suping ; Fang, Lixin ; Cai, Yingchun ; Zheng, Hao ; Zhang, Yishuang ; Zhou, Wen ; Cheng, Lei ; Cheng, Long ; Wang, Yiyi ; Qin, Lu

Objectives:

This research first investigated the effect of mesoporous silica nanoparticles (nMS) carrying chlorhexidine and silver (nMS-nAg-Chx) on periodontitis-related biofilms. This study aimed to investigate (1) the antibacterial activity on Porphyromonas gingivalis (P. gingivalis) biofilm; (2) the suppressing effect on virulence of P. gingivalis biofilm; (3) the regulating effect on periodontitis-related multispecies biofilm.

Methods:

Silver nanoparticles (nAg) and chlorhexidine (Chx) were co-loaded into nMS to form nMS-nAg-Chx. Inhibitory zone test and minimum inhibitory concentration (MIC) against P. gingivalis were tested. Growth curves, crystal violet (CV) staining, live/dead staining and scanning electron microscopy (SEM) observation were performed. Biofilm virulence was assessed. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and Quantitative Real Time-PCR (qPCR) were performed to validate the activity and composition changes of multispecies biofilm (P. gingivalis, Streptococcus gordonii and Streptococcus sanguinis).

Results:

nMS-nAg-Chx inhibited P. gingivalis biofilm dose-dependently (p<0.05), with MIC of 18.75 µg/mL. There were fewer live bacteria, less biomass and less virulence in nMS-nAg-Chx groups (p<0.05). nMS-nAg-Chx inhibited and modified periodontitis-related biofilms. The proportion of pathogenic bacteria decreased from 16.08 to 1.07% and that of helpful bacteria increased from 82.65 to 94.31% in 25 μg/mL nMS-nAg-Chx group for 72 h.

Conclusions:

nMS-nAg-Chx inhibited P. gingivalis growth, decreased biofilm virulence and modulated periodontitis-related multispecies biofilms toward healthy tendency. pH-sensitive nMS-nAg-Chx inhibit the pathogens and regulate oral microecology, showing great potential in periodontitis adjunctive therapy.

News (Medical) associated with Chlorhexidine Acetate

24 Jul 2024

·www.globenewswire.com

Teleflex Announces the Teleflex Center for Antimicrobial Protection

WAYNE, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the establishment of the Teleflex Center for Antimicrobial Protection (TCAP) as a strategic branch of its Vascular Access business unit led by Chuck Gartner, Director of Marketing - Strategic Initiatives. The Teleflex Center for Antimicrobial Protection, located in Research Triangle, North Carolina, is dedicated to reducing the spread of infections caused by multidrug-resistant organisms. Too often patients are exposed to these “superbugs” which can lead to additional complications and an increased length of stay in a hospital setting.1 Through education and partnership with professionals in infection prevention, TCAP seeks to be a resource for patients, physicians, and healthcare organizations. “Teleflex strives to deliver vascular access products that are designed to benefit both clinicians and patients by helping to reduce vascular access related complications,” said Lisa Kudlacz, President and General Manager, Teleflex Vascular. “We are proud of TCAP’s commitment to antimicrobial catheter technology and our ability to reduce the colonization of major pathogens linked to central line associated blood stream infections (CLABSI).”2 The Teleflex Center for Antimicrobial Protection aims to provide quality products, services, and education to its customers by pioneering catheter protection technology and developing innovative vascular access devices. TCAP recently sponsored an educational webinar focused on the expansion of surveillance of healthcare-acquired infections (HAI), specifically central line-associated bloodstream infections (CLABSI). That webinar can be viewed on-demand through Teleflex Academy. Teleflex, through its Arrow™ Brand of Vascular Access Products, has the only comprehensive portfolio of antimicrobial Chlorhexidine catheters designed to provide broad-spectrum protection against gram-positive, gram-negative, and fungal pathogens.2,3,4 Additionally, Arrow™ Maximal Barrier Kitting options provide protection for patients and improve procedural efficiency for clinicians.5 This portfolio of products was showcased at the Association for Professionals in Infection Control and Epidemiology (APIC) 2024 Annual Conference. During the conference, TCAP sponsored an educational Exhibitor Theater session, focused on CLABSI trends. To learn more about Arrow™ Antimicrobial Catheter and Kitting Solutions, visit our website. About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com. Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue, Arrowg+ard Blue Advance, Arrowg+ard Blue Plus, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are trademarks or registered trademarks of their respective owners. © 2024 Teleflex Incorporated. All rights reserved. MC-009780 References: Toor H, Farr S, Savla P, Kashyap S, Wang S, Miulli DE. Prevalence of central line-associated bloodstream infections (CLABSI) in intensive care and medical-surgical units. Cureus. 2022;14(3):e22809.doi:10.7759/cureus.22809In vitro data on file 2010: AVER-004371 and AVER-004483. No correlation between in vitro/in vivo testing methods and clinical outcomes has currently been ascertained.Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of Central Venous Catheter-Related Bloodstream Infection With an 'Antiseptic-Impregnated Catheter: A Randomized, Controlled Trial. Annals of Internal Medicine, August 15, 1997, Vol. 127, Issue 4, pp. 257–266.Spangler D and Moss S. In-Vitro Assessment of Antimicrobial Activity of Three Commercially Available Central Venous Catheters. Poster by Arrow (Teleflex) International, Inc. Department of Applied Research. 2010-0406 v1Fenik Y, Celebi N, Wagner R, et al. Prepackaged central line kits reduce procedural mistakes during central line insertion: a randomized controlled prospective trial. BMC Medical Education. 2013;13:60. Published 2013 Apr 30. doi:10.1186/1472-6920-13-60. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645964/ Rx only Contraindications: The Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ Catheters are contraindicated for patients with known hypersensitivity to chlorhexidine, silver sulfadiazine and/or sulfa drugs. Clinical assessment of the patient must be completed to ensure no contraindications exist. The Arrowg+ard Blue Advance™ Catheters are contraindicated in the following areas: • Patients with known hypersensitivity to chlorhexidine• In presence of device related infections• In presence of previous or current thrombosis in the intended vessel or along the catheterized vessel pathway. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained. For complete indications, contraindications, warnings, precautions, and adverse reactions, please refer to each referenced product's full package insert. Contacts:TeleflexLawrence KeuschVice President, Investor Relations and Strategy Developmentinvestor.relations@teleflex.com610-948-2836

100 Deals associated with Chlorhexidine Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D07669	Chlorhexidine Acetate	S03AA04	DB00878

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Uterine Cervical Erosion	CN	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1982
Vaginitis	CN	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1982

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


PO413 (AAO2022)	Not Applicable	Endophthalmitis	-	0.05% Aqueous Chlorhexidine	vssbehgekh(gzceujrmwh) = yubnbvaajf pkwpqbikzo (bjwqsbprgs ) View more	Negative	29 Sep 2022
				0.05% Aqueous Chlorhexidine	vssbehgekh(gzceujrmwh) = rdfupaqgqf pkwpqbikzo (bjwqsbprgs ) View more
NCT04399161 (AEXPC, CTgov)	Phase 2/3	Dental Caries	60	Chlorhexidine (Group A (Chlorhexidine Mouthrinse))	xajervrzvw(owqysqbqrm) = ubokhoeajk dstyntnuzv (elqmrixmxy, zvhyfwlgxg - kstxsmnmqf) View more	-	22 Jul 2020
				Xylitol (Group B (Xylitol Mouth Rinse))	xajervrzvw(owqysqbqrm) = ruatxmzmqc dstyntnuzv (elqmrixmxy, bzxyvoawoy - zqdvrokylo) View more
NCT00357877 (CTgov)	Phase 3	Dental Caries	983	Placebo	lfotxdirlh(qykbpsmpht) = xpovykdegz bwtcfywinl (kjlqqarwww, cbornxlpxv - rtclxezkwi) View more	-	14 Jun 2017
Pubmed \| Heart Lung	Not Applicable	-	-	Chlorhexidine gluconate by spray	pqidsiwnku(joqihcxsrw) = hmsdtktlrh nggpjmzkwe (zyeuwqhujl )	Positive	01 Mar 2004
				Chlorhexidine gluconate by swab	pqidsiwnku(joqihcxsrw) = zhbobihhjp nggpjmzkwe (zyeuwqhujl )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis